Evofem Biosciences, Inc.

EVFM

Evofem Biosciences, Inc.

EVFM

Insider Sentiment (TTM):

Last Purchase:2022-05-27Last Sale:2024-01-12Shares Purchased (TTM):0Shares Sold (TTM):0

Institutional Sentiment:

As of:2022-09-30Institutional Shares Owned:841Shares Outstanding:659,480Institutional Ownership Pct.:0.13%

Earnings Market Reaction:

Filing Date:2026-08-14Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Restricted Cash Current	-	-	-	1	1	1	1	1	1	1	1	0
Cash And Cash Equivalents At Carrying Value	-	1	1	-	-	0	1	-	-	-	-	-
Restricted Cash And Cash Equivalents At Carrying V…	0	1	-	-	-	-	-	-	-	-	-	-
Accounts Receivable Net Current	2	1	12	4	5	1	10	5	5	4	6	6
Inventory Net	2	2	1	2	2	2	2	1	1	1	2	3
Prepaid Expense And Other Assets Current	1	1	1	1	1	1	1	1	1	1	1	2
Assets Current	6	6	15	8	9	6	14	9	7	7	9	12
Property Plant And Equipment Net	0	0	0	0	0	0	0	1	1	1	1	2
Operating Lease Right Of Use Asset	0	0	0	0	0	0	0	0	0	0	0	0
Finite Lived Intangible Assets Net	1	1	4	5	5	6	10	14	-	-	-	-
Other Assets Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Assets	8	7	20	14	14	13	24	24	9	8	11	13
Liabilities And Stockhold…
Liabilities Current
Convertible Notes Payable Current	-	-	-	-	-	-	-	-	-	-	15	13
Accounts Payable Current	12	12	13	12	12	11	16	17	16	16	17	16
Short Term Borrowings	0	-	0	0	0	-	0	0	0	-	-	-
Accrued Liabilities Current	2	1	1	1	3	3	6	5	5	5	4	5
Employee Related Liabilities Current	2	1	3	4	3	3	3	3	3	3	3	2
Operating Lease Liability Current	0	0	0	0	0	0	0	0	0	0	0	0
Derivative Liabilities Current	7	1	1	1	0	0	1	0	1	4	2	-
Other Liabilities Current	11	10	12	8	8	7	7	-	4	3	3	4
Liabilities Current	89	79	85	78	74	71	80	76	73	74	72	68
Operating Lease Liability Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Liabilities	90	80	90	84	79	78	90	90	73	74	72	68
Temporary Equity Carrying…
Temporary Equity Carrying Amount Attributable To P…	5	5	5	5	5	5	5	5	5	5	5	2
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	-
Stockholders Equity
Additional Paid In Capital	832	832	832	832	831	829	829	825	824	823	823	829
Accumulated Other Comprehensive Income Loss Net Of…	-5	-7	-9	-7	-3	-2	-3	-2	-1	-1	-1	-0
Retained Earnings Accumulated Deficit	-914	-903	-897	-900	-898	-897	-898	-895	-892	-894	-889	-885
Stockholders Equity	-88	-78	-74	-75	-70	-70	-71	-71	-69	-71	-67	-56
Temporary Equity Shares Issued	-	-	-	-	-	-	-	-	-	-	0	0
Liabilities And Stockholders Equity	8	7	20	14	14	13	24	24	9	8	11	13
Temporary Equity Shares Outstanding	-	-	-	-	-	-	-	-	-	-	0	0
Temporary Equity Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	5	5	5	5	5	5	5	5	5	5	5	5
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	3,000	3,000	3,000	3,000	3,000	3,000	3,000	3,000	3,000	3,000	3,000	3,000
Common Stock Shares Issued	133	133	127	124	119	113	113	100	83	49	20	6
Shares Outstanding	133	133	127	124	119	113	113	100	83	49	20	6

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	14.29%	14.29%	0.00%	-	-	-	-	-	-	-	-	-
2025	11.11%	11.11%	0.00%	0.00%	30.00%	0.00%	0.00%	0.00%	-10.00%	-11.11%	-22.22%	-22.22%
2024	-25.00%	-37.50%	-37.50%	0.00%	-10.00%	40.00%	0.00%	0.00%	0.00%	0.00%	0.00%	11.11%
2023	-	-	-	-	-	-	-4.29%	-24.29%	-57.14%	-42.31%	-42.31%	-50.00%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	0.07	0.08	0.18	0.10	0.12	0.08	0.17	0.11	0.10	0.09	0.13	0.17
Quick Ratio	0.03	0.04	0.15	0.07	0.08	0.03	0.13	0.08	0.07	0.07	0.09	0.10
Working Capital	-82.53M	-72.70M	-69.54M	-70.27M	-64.92M	-64.98M	-66.84M	-67.71M	-65.96M	-67.32M	-63.25M	-56.36M
Leverage & Debt
Debt to Equity	-1.03	-1.03	-1.21	-1.12	-1.14	-1.12	-1.27	-1.27	-1.06	-1.05	-1.09	-1.20
Interest Coverage TTM	-1.15	-0.63	1.43	-0.43	-1.91	-1.96	-3.37	-4.36	-4.88	-7.54	-7.86	-12.08
Debt Ratio	11.97	10.77	4.42	6.08	5.51	6.03	3.79	3.76	8.56	9.04	6.87	5.10
Efficiency & Turnover
Asset Turnover TTM	1.65	1.99	0.92	0.94	1.51	1.57	1.13	0.92	1.57	0.93	1.02	0.49
Days Sales Outstanding TTM	75.15	15.41	201.75	101.19	100.93	59.95	146.75	125.04	101.12	133.47	68.76	256.86
Receivables Turnover TTM	4.86	23.68	1.81	3.61	3.62	6.09	2.49	2.92	3.61	2.73	5.31	1.42
Per Share Metrics
Diluted EPS TTM	-0.11	-0.05	0.00	-0.05	-0.05	-0.00	-0.11	-0.08	0.04	1.62	0.05	0.06
Free Cash Flow Per Share TTM	-0.02	-0.00	-0.02	-0.04	-0.05	-0.03	-0.06	-0.02	-0.05	-0.13	-1.86	-3.63
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	75.52%	76.96%	77.12%	80.05%	79.73%	78.83%	80.20%	80.84%	75.75%	63.65%	64.26%	56.18%
Operating Profit Margin TTM	-15.31%	-7.53%	16.71%	-5.51%	-25.29%	-27.13%	-39.64%	-58.80%	-63.03%	-106.87%	-97.96%	-195.57%
Net Profit Margin TTM	-85.32%	-30.36%	1.36%	-30.97%	-36.43%	-19.29%	-46.30%	-46.72%	340.89%	315.54%	290.81%	331.34%
Growth Metrics
Net Revenue Growth (1Y)	4.49%	21.87%	4.23%	3.67%	-2.51%	3.70%	6.28%	26.09%	19.54%	-12.95%	8.20%	-32.96%
Net Income Growth (1Y)	144.73%	91.82%	-103.06%	-31.28%	-110.42%	-106.34%	-116.92%	-117.78%	-11.76%	-207.31%	-169.07%	-138.05%
EPS Growth (1Y)	114.72%	70.11%	-101.98%	-44.57%	-105.77%	-101.67%	-101.02%	-100.78%	-97.92%	-104.37%	-106.67%	-105.92%
Valuation Metrics
P/E TTM	-0.07	-0.20	4.51	-0.26	-0.19	-0.33	-0.09	-0.11	0.01	0.01	0.01	0.02
P/B TTM	-0.01	-0.02	-0.02	-0.02	-0.02	-0.02	-0.01	-0.01	-0.01	-0.01	-0.00	-0.01
P/S TTM	0.06	0.06	0.06	0.08	0.07	0.06	0.04	0.05	0.04	0.05	0.02	0.05
Market Cap	1.10M	1.20M	1.24M	1.43M	1.20M	1.06M	800.03K	868.13K	734.51K	748.67K	308.91K	677.84K
Enterprise Value	1.18M	-1.18M	805.58K	885.94K	839.94K	-45.52K	194.03K	414.13K	439.51K	59.67K	14.46M	13.38M
Calculated Values
Free Cash Flow TTM	-2.22M	-315.00K	-2.11M	-5.15M	-6.46M	-4.06M	-4.45M	-2.17M	-3.57M	-3.92M	-8.97M	-15.37M
Net Debt	77.00K	-2.38M	-431.00K	-549.00K	-365.00K	-1.11M	-606.00K	-454.00K	-295.00K	-689.00K	14.15M	12.70M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2024-01-12Sale

Owner: Zhang, Yan

Title: CFO

Shares: 104

Price/Share: $0.04

Value: $4.16

Shares Owned: -

Relationship: Officer

Ownership: Direct

2023-12-21Sale

Owner: Kamdar, Kim P.

Title: -

Shares: 10

Price/Share: $0.62

Value: $6.20

Shares Owned: -

Relationship: Director

Ownership: Direct

2022-05-27Purchase

Owner: Pelletier, Saundra L

Title: Chief Executive Officer

Shares: 141,000

Price/Share: $0.35

Value: $49,350.00

Shares Owned: 236,722

Relationship: Director,Officer

Ownership: Direct

2021-12-20Purchase

Owner: Fitzpatrick, Alexander A

Title: General Counsel and Secretary

Shares: 25,000

Price/Share: $0.39

Value: $9,750.00

Shares Owned: 336,422

Relationship: Officer

Ownership: Direct

2021-12-20Purchase

Owner: Pelletier, Saundra L

Title: Chief Executive Officer

Shares: 135,000

Price/Share: $0.38

Value: $51,300.00

Shares Owned: 985,837

Relationship: Director,Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2024-01-12	Zhang, Yan	Officer	CFO	Direct	Sale	104	0.04	$4.16	0	4
2023-12-21	Kamdar, Kim P.	Director	-	Direct	Sale	10	0.62	$6.20	0	4
2022-05-27	Pelletier, Saundra L	Director,Officer	Chief Executive Officer	Direct	Purchase	141,000	0.35	$49,350.00	236,722	4
2021-12-20	Fitzpatrick, Alexander A	Officer	General Counsel and Secretary	Direct	Purchase	25,000	0.39	$9,750.00	336,422	4
2021-12-20	Pelletier, Saundra L	Director,Officer	Chief Executive Officer	Direct	Purchase	135,000	0.38	$51,300.00	985,837	4
2021-12-20	File, Justin J.	Officer	Chief Financial Officer	Direct	Purchase	40,594	0.37	$15,019.78	480,982	4
2021-06-18	Kamdar, Kim P.	Director	-	Direct	Purchase	10,000	1.17	$11,700.00	19,287	4
2021-06-14	O'Brien, Anthony Stephen	Director	-	Direct	Purchase	8,140	1.31	$10,663.40	8,140	4
2021-06-11	Rarick, Lisa Dale	Director	-	Direct	Purchase	5,000	1.20	$6,000.00	10,250	4
2021-06-11	Barrans, Russell	Officer	Chief Commercial Officer	Direct	Purchase	18,180	1.14	$20,725.20	468,552	4
2021-06-10	File, Justin J.	Officer	Chief Financial Officer	Direct	Purchase	24,500	1.03	$25,235.00	440,388	4
2021-06-10	Pelletier, Saundra L	Director,Officer	Chief Executive Officer	Direct	Purchase	50,000	1.03	$51,500.00	850,837	4
2021-06-10	Fitzpatrick, Alexander A	Officer	General Counsel and Secretary	Direct	Purchase	10,000	1.03	$10,300.00	311,422	4
2021-03-09	Pelletier, Saundra L	Director,Officer	Chief Executive Officer	Direct	Purchase	45,249	2.28	$103,167.72	906,137	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2022-09-30

0.13%

Inst. Shares: 841

Shares Outstanding: 659,480

2022-06-30

Inst. Shares: 7,595,294

Shares Outstanding: 217,028

2022-03-31

Inst. Shares: 19,679,664

Shares Outstanding: 88,741

2021-12-31

269.75%

Inst. Shares: 23,542,182

Shares Outstanding: 8,727,253

2021-09-30

260.28%

Inst. Shares: 26,768,264

Shares Outstanding: 10,284,365

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2022-09-30	841	659,480	0.13%
2022-06-30	7,595,294	217,028	-
2022-03-31	19,679,664	88,741	-
2021-12-31	23,542,182	8,727,253	269.75%
2021-09-30	26,768,264	10,284,365	260.28%
2021-06-30	35,784,542	8,344,571	-
2021-03-31	42,581,879	5,456,221	-
2020-12-31	33,203,155	4,479,390	-
2020-09-30	36,323,693	5,416,447	-
2020-06-30	41,791,551	3,848,358	-
2020-03-31	37,313,939	3,848,358	-
2019-12-31	30,197,756	3,210,797	-
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Evofem Biosciences, Inc. (EVFM) — SEC Financial Statements & Analysis

Evofem Biosciences, Inc. (EVFM) is a pharmaceutical preparations company, incorporated in DE. Evofem Biosciences, Inc. trades on OTC as: EVFM. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Evofem Biosciences, Inc. reported a 4.49% year-over-year revenue growth, a Gross Profit Margin of 75.52% (TTM), a Debt-to-Equity ratio of -1.03x, a Price-to-Sales (P/S) ratio of 0.06x (TTM), a Price-to-Book (P/B) ratio of -0.01x (TTM), at a market cap of $1.10M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 4.49%
Gross Profit Margin TTM: 75.52%
Debt To Equity: -1.03x
P/S TTM: 0.06x
P/B TTM: -0.01x
Market Cap: $1.10M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Evofem Biosciences, Inc. in?

Evofem Biosciences, Inc. (EVFM) operates in the Pharmaceutical Preparations industry.

What is EVFM's market cap?

Evofem Biosciences, Inc. (EVFM) has a market capitalization of $1.10M as of 2026-06-30.

What exchange does EVFM trade on?

Evofem Biosciences, Inc. (EVFM) trades on the OTC.

Where is Evofem Biosciences, Inc. incorporated?

Evofem Biosciences, Inc. is incorporated in DE.